These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 33759081)

  • 1. Treatment Persistence and Adherence Among Patients With Psoriatic Arthritis Who Initiated Targeted Immune Modulators in the US: A Retrospective Cohort Study.
    Walsh JA; Cai Q; Lin I; Pericone CD; Chakravarty SD
    Adv Ther; 2021 May; 38(5):2353-2364. PubMed ID: 33759081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
    Murage MJ; Princic N; Park J; Malatestinic WN; Zhu B; Atiya B; Kern SA; Stenger KB; Sprabery AT; Ogdie A
    J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database.
    Strunz PP; Englbrecht M; Risser LM; Witte T; Froehlich M; Schmalzing M; Gernert M; Schmieder A; Bartz-Bazzanella P; von der Decken C; Karberg K; Gauler G; Wurth P; Späthling-Mestekemper S; Kuhn C; Vorbrüggen W; Heck J; Welcker M; Kleinert S
    Front Immunol; 2024; 15():1395968. PubMed ID: 38846940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis.
    Rosenberg V; Amital H; Chodick G; Faccin F; Gendelman O
    Drugs Aging; 2024 Aug; 41(8):685-697. PubMed ID: 39106030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS).
    Marcombes C; Penso L; Weill A; Dray-Spira R; Zureik M; Sbidian E
    Br J Dermatol; 2023 Oct; 189(5):561-568. PubMed ID: 37479503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS).
    Pina Vegas L; Hoisnard L; Bastard L; Sbidian E; Claudepierre P
    RMD Open; 2022 Dec; 8(2):. PubMed ID: 36597983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study.
    Kristensen LE; Ng KJ; Ngantcha M; Morel J; Lubrano E; Tillett W; Alten R; Chandran V; Martinez Ferrer À; Zhu B; Kennedy D; Holzkämper T; Gullick N; Kronbergs A; Fakhouri W; de la Torre I; McGonagle DG
    RMD Open; 2024 Sep; 10(3):. PubMed ID: 39306343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of a second TNFi vs other biologic or targeted synthetic DMARD following an initial TNFi.
    Asante K; Racsa P; Bloomfield A; Cornett D; Schwab P
    J Manag Care Spec Pharm; 2023 Oct; 29(10):1109-1118. PubMed ID: 37776118
    [No Abstract]   [Full Text] [Related]  

  • 9. Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database.
    Mease PJ; Young P; Gruben D; Fallon L; Germino R; Kavanaugh A
    Adv Ther; 2022 Jun; 39(6):2932-2945. PubMed ID: 35482248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses from an Administrative Claims Database.
    Walsh JA; Adejoro O; Chastek B; Palmer JB; Hur P
    J Manag Care Spec Pharm; 2018 Jul; 24(7):623-631. PubMed ID: 29952704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
    Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
    Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations.
    Leung YY; Korotaeva TV; Candia L; Pedersen SJ; Bautista Molano W; Ruderman EM; Bisoendial R; Perez-Alamino R; Olsder W; Möller B; Grazio S; Gudu T; Mody GM; Pineda C; Raffayova H; Rohekar S; Goldenstein-Schainberg C; Gutierrez Urena SR; Casasola Vargas JC; Meghnathi B; Prasad R; Richette P; Miranda JRS; Malliotis N; Lindqvist U; Simon D; Ezeonyeji A; Soriano ER; FitzGerald O
    J Rheumatol; 2023 Jan; 50(1):119-130. PubMed ID: 36243409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study.
    Zhu B; Edson-Heredia E; Gatz JL; Guo J; Shuler CL
    Clin Ther; 2013 Sep; 35(9):1376-85. PubMed ID: 23954091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry.
    Mease PJ; Karki C; Liu M; Li Y; Gershenson B; Feng H; Hur P; Greenberg JD
    RMD Open; 2019; 5(1):e000880. PubMed ID: 31168408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Systematic Overview of Contraindications and Special Warnings for Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs: Establishing a Framework to Create a "Safety Checklist".
    Skaarup L; Ingrid E; Sepriano A; Nikiphorou E; Østgård R; Lauper K; Grosse-Michaelis I; Kloppenburg M; Glintborg B; Liew DFL; Kragstrup TW
    Drug Saf; 2024 Nov; 47(11):1075-1093. PubMed ID: 39012469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors.
    Walsh JA; Lin I; Zhao R; Shiff NJ; Morrison L; Emond B; Yu LH; Schwartzbein S; Lefebvre P; Pilon D; Chakravarty SD; Mease P
    Drugs Real World Outcomes; 2024 Sep; 11(3):487-499. PubMed ID: 39083163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry.
    Harrold LR; Stolshek BS; Rebello S; Collier DH; Mutebi A; Wade SW; Malley W; Greenberg JD; Etzel CJ
    Clin Rheumatol; 2017 Apr; 36(4):895-901. PubMed ID: 28271234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient characteristics associated with use of TNF vs interleukin inhibitors as first-line biologic treatment for psoriatic arthritis.
    Jin Y; Chen SK; Lee H; Landon JE; Merola JF; Kim SC
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1106-1117. PubMed ID: 34337987
    [No Abstract]   [Full Text] [Related]  

  • 19. Real-world evaluation of persistence, effectiveness and usage patterns of tofacitinib in treatment of psoriatic arthritis in Australia.
    Littlejohn G; Leadbetter J; Butcher BE; Feletar M; O'Sullivan C; Smith T; Witcombe D; Ng HY; Youssef P
    Clin Rheumatol; 2024 May; 43(5):1579-1589. PubMed ID: 38459357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: a cohort study of 14 778 patients from the French health insurance database (SNDS).
    Pina Vegas L; Penso L; Sbidian E; Claudepierre P
    RMD Open; 2023 Dec; 9(4):. PubMed ID: 38114199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.